Stoke Therapeutics (STOK) Competitors $22.90 -0.60 (-2.55%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$22.81 -0.09 (-0.40%) As of 09/19/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STOK vs. KRYS, PCVX, ACAD, ACLX, ADMA, ARWR, MENS, MIRM, MLTX, and MTSRShould you be buying Stoke Therapeutics stock or one of its competitors? The main competitors of Stoke Therapeutics include Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry. Stoke Therapeutics vs. Its Competitors Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals MoonLake Immunotherapeutics Metsera Stoke Therapeutics (NASDAQ:STOK) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Which has more risk and volatility, STOK or KRYS? Stoke Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Do institutionals and insiders believe in STOK or KRYS? 86.3% of Krystal Biotech shares are owned by institutional investors. 9.5% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 13.7% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger earnings and valuation, STOK or KRYS? Krystal Biotech has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStoke Therapeutics$36.56M34.32-$88.98M$0.8526.94Krystal Biotech$290.52M16.29$89.16M$4.9233.25 Do analysts prefer STOK or KRYS? Stoke Therapeutics currently has a consensus target price of $25.57, indicating a potential upside of 11.67%. Krystal Biotech has a consensus target price of $209.00, indicating a potential upside of 27.77%. Given Krystal Biotech's higher probable upside, analysts plainly believe Krystal Biotech is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Is STOK or KRYS more profitable? Krystal Biotech has a net margin of 40.85% compared to Stoke Therapeutics' net margin of 26.25%. Stoke Therapeutics' return on equity of 18.32% beat Krystal Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Stoke Therapeutics26.25% 18.32% 15.48% Krystal Biotech 40.85%15.21%13.81% Does the media prefer STOK or KRYS? In the previous week, Krystal Biotech had 7 more articles in the media than Stoke Therapeutics. MarketBeat recorded 11 mentions for Krystal Biotech and 4 mentions for Stoke Therapeutics. Krystal Biotech's average media sentiment score of 0.90 beat Stoke Therapeutics' score of 0.87 indicating that Krystal Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 3 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKrystal Biotech beats Stoke Therapeutics on 10 of the 17 factors compared between the two stocks. Get Stoke Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STOK vs. The Competition Export to ExcelMetricStoke TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.29B$3.16B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio26.9420.5276.4826.75Price / Sales34.32446.54531.72124.23Price / CashN/A46.0037.9261.55Price / Book5.309.6613.726.40Net Income-$88.98M-$53.02M$3.29B$271.62M7 Day Performance-2.39%3.12%2.66%3.46%1 Month Performance18.53%7.57%6.02%9.87%1 Year Performance66.55%11.17%80.02%28.45% Stoke Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STOKStoke Therapeutics3.8319 of 5 stars$22.90-2.6%$25.57+11.7%+51.3%$1.29B$36.56M26.94100High Trading VolumeKRYSKrystal Biotech4.9554 of 5 stars$145.20-3.4%$210.38+44.9%-11.3%$4.35B$290.52M29.51210PCVXVaxcyte2.0083 of 5 stars$32.41-1.8%$130.00+301.1%-72.9%$4.29BN/A-7.89160Positive NewsACADACADIA Pharmaceuticals4.1484 of 5 stars$25.39+0.5%$28.88+13.7%+48.7%$4.26B$957.80M19.09510Positive NewsACLXArcellx2.3311 of 5 stars$71.11-2.1%$114.31+60.7%-8.9%$4.03B$107.94M-20.7980Positive NewsInsider TradeADMAADMA Biologics3.5097 of 5 stars$16.42-2.7%$27.67+68.5%-19.4%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.2169 of 5 stars$27.17-6.6%$43.14+58.8%+45.2%$4.02B$3.55M-21.23400Insider TradeAnalyst RevisionMENSJyong BiotechN/A$55.68+6.4%N/AN/A$3.98BN/A0.0031News CoverageHigh Trading VolumeMIRMMirum Pharmaceuticals2.9868 of 5 stars$77.39+1.7%$74.13-4.2%+89.0%$3.82B$336.89M-63.96140MLTXMoonLake Immunotherapeutics2.668 of 5 stars$61.12+2.8%$74.43+21.8%+0.1%$3.82BN/A-21.992MTSRMetseraN/A$35.10-2.1%$59.00+68.1%N/A$3.77BN/A0.0081 Related Companies and Tools Related Companies KRYS Alternatives PCVX Alternatives ACAD Alternatives ACLX Alternatives ADMA Alternatives ARWR Alternatives MENS Alternatives MIRM Alternatives MLTX Alternatives MTSR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STOK) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWhy silver could go 100X higherInflation is destroying purchasing power at 10–14% per year. Gold will protect you — but not the way you think...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STOK Stock Alerts